Daniel R. Gomez
YOU?
Author Swipe
View article: What Is the Cost Impact of Second Opinions in Oncology? A Retrospective Review
What Is the Cost Impact of Second Opinions in Oncology? A Retrospective Review Open
PURPOSE Second opinions in oncology may optimize treatment plans, resulting in improved outcomes such as prognosis and morbidity. Changes in treatment plans are often de-escalations in treatment intensity. However, data on the cost impact …
View article: SURG-18. Results Utilizing the Tumor-Targeting Fluorescence Imaging Agent Tozuleristide and the Canvas Imaging System in an Exploratory Cohort of Adults Undergoing Resection of Vestibular Schwannoma
SURG-18. Results Utilizing the Tumor-Targeting Fluorescence Imaging Agent Tozuleristide and the Canvas Imaging System in an Exploratory Cohort of Adults Undergoing Resection of Vestibular Schwannoma Open
INTRODUCTION This investigator-initiated study evaluated tozuleristide (Blaze Bioscience, Inc.), a tumor-targeting near-infrared fluorescence-guided surgery (FGS) imaging agent in combination with the Canvas imaging system (Blaze Bioscienc…
View article: Thymus Composition, Disease Control, and Toxicity in Locally Advanced Lung Cancer
Thymus Composition, Disease Control, and Toxicity in Locally Advanced Lung Cancer Open
Thymic involution, characterized by adipose replacement of functional thymic tissue, is a broadly recognized feature of age-related immunosenescence. Currently, no established, non-invasive method measures residual thymus in adults, its re…
View article: Prospective validation of a pretreatment 18F-FDG PET/CT and mean lung dose model for early radiation pneumonitis
Prospective validation of a pretreatment 18F-FDG PET/CT and mean lung dose model for early radiation pneumonitis Open
The previously developed SUVP90 and MLD-based risk model for RPEarly demonstrated a high probability to correctly predict RPEarly in the independent cohort. This now validated RPEarly risk model with derived high-risk indications could ena…
View article: A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC)
A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC) Open
NCT05657873, registered 12/12/2022.
View article: Probiotic supplementation mitigates sex-dependent nociceptive changes and gut dysbiosis induced by prenatal opioid exposure
Probiotic supplementation mitigates sex-dependent nociceptive changes and gut dysbiosis induced by prenatal opioid exposure Open
The gut microbiome has emerged as a promising target for modulating adverse effects of opioid exposure due to its significant role in health and disease. Opioid use disorder (OUD) has become increasingly prevalent, specifically in women of…
View article: Automated real-world data integration improves cancer outcome prediction
Automated real-world data integration improves cancer outcome prediction Open
The digitization of health records and growing availability of tumour DNA sequencing provide an opportunity to study the determinants of cancer outcomes with unprecedented richness. Patient data are often stored in unstructured text and si…
View article: Real-world Decision-making Process for Stereotactic Body Radiotherapy Versus Minimally Invasive Surgery in Early-stage Lung Cancer Patients
Real-world Decision-making Process for Stereotactic Body Radiotherapy Versus Minimally Invasive Surgery in Early-stage Lung Cancer Patients Open
Objective: To generate a prediction model for selection of treatment modality for early-stage non-small cell lung cancer (NSCLC). Summary Background Data: Stereotactic body radiotherapy (SBRT) and minimally invasive surgery (MIS) are used …
View article: Supplementary Figure 26 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer
Supplementary Figure 26 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer Open
Supplementary Figure 26. Proportion of (A) tumor, (B) non-tumor, and (C) total PD-L1+ cells according to ATM/TP53 co-mutation status.
View article: Supplementary Table 2 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer
Supplementary Table 2 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer Open
Supplementary Table 2. List of potential ATM germline variants identified among 3800 patients with NSCLC at the DFCI
View article: Supplementary Figure 1. from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer
Supplementary Figure 1. from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer Open
Supplementary Figure 1. (A) ATM mutation classification schema (B) Lollipop plot of all 714 mutations in the ATM gene identified in the combined DFCI/MSK cohort. (C) Lollipop plot of all 152 benign mutations in the ATM gene identified in t…
View article: Supplementary Table 3 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer
Supplementary Table 3 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer Open
Supplementary Table 3. Baseline clinicopathologic features of patients with ATMMUT and ATMWT NSCLC at the Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center.
View article: Supplementary Figure 17 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer
Supplementary Figure 17 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer Open
Supplementary Figure 17. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 inhibition among patients with advanced/metastatic NSCLC, according to ATM expression by immunohistochemistry.
View article: Supplementary Figure 13 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer
Supplementary Figure 13 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer Open
Supplementary Figure 13. Overall survival since the date of initial diagnosis among patients with stage IV NSCLC according to ATM expression by immunohistochemistry.
View article: Supplementary Table S1 from Tumor-targeted non-ablative radiation promotes solid tumor CAR T-cell therapy efficacy
Supplementary Table S1 from Tumor-targeted non-ablative radiation promotes solid tumor CAR T-cell therapy efficacy Open
List of antibodies and reagents used in this study
View article: Supplementary Figure 24 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer
Supplementary Figure 24 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer Open
Supplementary Figure 24. (A) Intratumoral, (B) tumor-stroma interface, and (C) total CD8+ T cells according to ATM/TP53 co-mutation status. (D) Intratumoral, (E) tumor-stroma interface, and (F) total PD1+ immune cells according to ATM/TP53…
View article: Supplementary Figure 29 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer
Supplementary Figure 29 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer Open
Supplementary Figure 29. Box plot showing immune cell subsets significantly enriched among ATMMUT versus ATMWT NSCLC as assessed by deconvoluting bulky RNAseq data from the TCGA-NSCLC dataset. Non-significant results are not shown.
View article: Data from Tumor-targeted non-ablative radiation promotes solid tumor CAR T-cell therapy efficacy
Data from Tumor-targeted non-ablative radiation promotes solid tumor CAR T-cell therapy efficacy Open
Infiltration of tumor by T cells is a prerequisite for successful immunotherapy of solid tumors. In this study, we investigate the influence of tumor-targeted radiation on chimeric antigen receptor (CAR) T-cell therapy tumor infiltration, …
View article: Supplementary Figure 9 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer
Supplementary Figure 9 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer Open
Supplementary Figure 9. (A) Disease free- and overall survival among patients with (A) stage I, and (B) stage II NSCLC according to ATM mutation status.
View article: Supplementary Figure 16 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer
Supplementary Figure 16 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer Open
Supplementary Figure 16. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 inhibition monotherapy among patients with advanced/metastatic NSCLC, according to ATM/TP53 co-mutation status. (D) Ob…
View article: Supplementary Table 3 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer
Supplementary Table 3 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer Open
Supplementary Table 3. Baseline clinicopathologic features of patients with ATMMUT and ATMWT NSCLC at the Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center.
View article: Supplementary Figure 23. from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer
Supplementary Figure 23. from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer Open
Supplementary Figure 23. Correlation of intratumoral, tumor-stroma interface, and total CD8+, PD1+, CD8+PD1+, FOXP3+ T cells and tumoral and non-tumoral PD-L1+ cells among ATMMUT NSCLCs.
View article: Supplementary Table 4 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer
Supplementary Table 4 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer Open
Supplementary Table 4. Baseline clinicopathologic features of patients with ATM mutated NSCLC according ATM protein expression by immunohistochemistry.
View article: Supplementary Table 6 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer
Supplementary Table 6 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer Open
Supplementary Table 6. Baseline clinicopathologic features of patients with ATM mutated NSCLC according ATM protein expression by immunohistochemistry.
View article: Supplementary Figure 15 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer
Supplementary Figure 15 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer Open
Supplementary Figure 15. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to chemo-immunotherapy among patients with advanced/metastatic PD-L1 negative (<1%) NSCLC, according to ATM mutation status. (D) …
View article: Supplementary Figure 8 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer
Supplementary Figure 8 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer Open
Supplementary Figure 8. Oncoprint plot showing the distribution of the most commonly mutated genes in NSCLCs with complete ATM loss by IHC (ATMLOST), intact ATM expression (ATMINTACT), and ATM heterogeneous loss (ATMHET LOST) by IHC.
View article: Supplementary Figure 11 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer
Supplementary Figure 11 from Clinicopathologic, genomic, and immunophenotypic landscape of <i>ATM </i>mutations in non-small cell lung cancer Open
Supplementary Figure 11. Overall survival since the date of initial diagnosis among patients with stage IV NSCLC according to ATM mutation status.